To determine whether FBXL5 expression is also downregulated in more differentiated hematopoietic progenitor cells in MDS patients, we evaluated a published set of microarray data for CD34+ hematopoietic progenitor cells from 183 MDS patients with various cytogenetic abnormalities and 17 healthy control subjects28. Here, FBXL5 is linked to myelodysplastic syndrome.